Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals Inc. will work with a Watertown biotech on new gene-editing therapies for people with sickle cell ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

This was the stock's third consecutive day of gains.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with ...

VERX's strong portfolio, increasing customer base and product integrations make it a compelling investment option at present.

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...